JP2013530931A - 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用 - Google Patents

液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用 Download PDF

Info

Publication number
JP2013530931A
JP2013530931A JP2013505286A JP2013505286A JP2013530931A JP 2013530931 A JP2013530931 A JP 2013530931A JP 2013505286 A JP2013505286 A JP 2013505286A JP 2013505286 A JP2013505286 A JP 2013505286A JP 2013530931 A JP2013530931 A JP 2013530931A
Authority
JP
Japan
Prior art keywords
dosage form
poly
active ingredient
biologically active
propofol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530931A5 (enExample
Inventor
フランソワ ラヴネール
ドロテー ル・ギャレック
ダビッド レサール
サンドラ ゴリ
デーモン スミス
ミルー ラームニ
ヴィナヤック サン
Original Assignee
ラボファーマ インコーポレイテッド
ラボファーマ（バルバドス）リミテッド
ラボファーマ ヨーロッパ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボファーマ インコーポレイテッド, ラボファーマ（バルバドス）リミテッド, ラボファーマ ヨーロッパ リミテッド filed Critical ラボファーマ インコーポレイテッド
Publication of JP2013530931A publication Critical patent/JP2013530931A/ja
Publication of JP2013530931A5 publication Critical patent/JP2013530931A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013505286A 2010-04-23 2011-04-21 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用 Pending JP2013530931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32734810P 2010-04-23 2010-04-23
US61/327,348 2010-04-23
PCT/CA2011/000447 WO2011130834A1 (en) 2010-04-23 2011-04-21 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017094186A Division JP6572256B2 (ja) 2010-04-23 2017-05-10 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用

Publications (2)

Publication Number Publication Date
JP2013530931A true JP2013530931A (ja) 2013-08-01
JP2013530931A5 JP2013530931A5 (enExample) 2014-05-29

Family

ID=44833585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505286A Pending JP2013530931A (ja) 2010-04-23 2011-04-21 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
JP2017094186A Active JP6572256B2 (ja) 2010-04-23 2017-05-10 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017094186A Active JP6572256B2 (ja) 2010-04-23 2017-05-10 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用

Country Status (6)

Country Link
US (1) US20130039864A1 (enExample)
EP (1) EP2563349A4 (enExample)
JP (2) JP2013530931A (enExample)
CA (1) CA2797098C (enExample)
IL (1) IL222568A (enExample)
WO (1) WO2011130834A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017186346A (ja) * 2010-04-23 2017-10-12 パラディン ラブス インコーポレーテッド 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
JP2018058794A (ja) * 2016-10-06 2018-04-12 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
JP2023528414A (ja) * 2020-06-02 2023-07-04 パーデュー・リサーチ・ファウンデーション 平衡ナノ沈殿による単分散性動力学的凍結ポリマーミセルの製剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
GB2561009B (en) * 2017-03-31 2020-05-13 Altus Formulation Inc Non-ionic PVP-PLA block copolymers and pharmaceutical compositions derived therefrom

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206841A (ja) * 2000-01-24 2001-07-31 Pfizer Prod Inc 迅速崩壊・急速溶解固形剤形
JP2004501180A (ja) * 2000-06-29 2004-01-15 ラボファーム，インコーポレーテッド ポリマーミセル組成物
JP2004505033A (ja) * 2000-08-01 2004-02-19 ユニバーシティ　オブ　フロリダ 薬物を可溶化するための新規なマイクロエマルジョンおよびミセルシステム
JP2005526771A (ja) * 2002-03-18 2005-09-08 ラボファーマ インコーポレイテッド 殺菌安定化ナノ分散物の調製
JP2006507276A (ja) * 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド 放出制御組成物
JP2006528179A (ja) * 2003-07-23 2006-12-14 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
JP2007524661A (ja) * 2003-12-17 2007-08-30 エムジーアイ ジーピー インコーポレイティッド 長期鎮静のためのプロポフォールの水溶性プロドラッグの投与の方法
JP2008521755A (ja) * 2004-11-29 2008-06-26 ラボファーム インコーポレイテッド 液体生物活性物質の固体配合物
WO2009012303A2 (en) * 2007-07-16 2009-01-22 Northeastern University Therapeutic stable nanoparticles
WO2009040818A1 (en) * 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
WO2009133325A2 (fr) * 2008-04-29 2009-11-05 Les Laboratoires Servier Micelles polymerisees
JP2010504318A (ja) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド ｐＨ標的化薬剤送達のための組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130834A1 (en) * 2010-04-23 2011-10-27 Labopharm Inc. Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206841A (ja) * 2000-01-24 2001-07-31 Pfizer Prod Inc 迅速崩壊・急速溶解固形剤形
JP2004501180A (ja) * 2000-06-29 2004-01-15 ラボファーム，インコーポレーテッド ポリマーミセル組成物
JP2004505033A (ja) * 2000-08-01 2004-02-19 ユニバーシティ　オブ　フロリダ 薬物を可溶化するための新規なマイクロエマルジョンおよびミセルシステム
JP2005526771A (ja) * 2002-03-18 2005-09-08 ラボファーマ インコーポレイテッド 殺菌安定化ナノ分散物の調製
JP2006507276A (ja) * 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド 放出制御組成物
JP2006528179A (ja) * 2003-07-23 2006-12-14 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
JP2007524661A (ja) * 2003-12-17 2007-08-30 エムジーアイ ジーピー インコーポレイティッド 長期鎮静のためのプロポフォールの水溶性プロドラッグの投与の方法
JP2008521755A (ja) * 2004-11-29 2008-06-26 ラボファーム インコーポレイテッド 液体生物活性物質の固体配合物
JP2010504318A (ja) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド ｐＨ標的化薬剤送達のための組成物及び方法
WO2009012303A2 (en) * 2007-07-16 2009-01-22 Northeastern University Therapeutic stable nanoparticles
WO2009040818A1 (en) * 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
WO2009133325A2 (fr) * 2008-04-29 2009-11-05 Les Laboratoires Servier Micelles polymerisees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
経口投与製剤の設計と評価, JPN6016013493, 1995, pages 247 - 248, ISSN: 0003297921 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017186346A (ja) * 2010-04-23 2017-10-12 パラディン ラブス インコーポレーテッド 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
JP2018058794A (ja) * 2016-10-06 2018-04-12 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
JP2023528414A (ja) * 2020-06-02 2023-07-04 パーデュー・リサーチ・ファウンデーション 平衡ナノ沈殿による単分散性動力学的凍結ポリマーミセルの製剤

Also Published As

Publication number Publication date
US20130039864A1 (en) 2013-02-14
IL222568A0 (en) 2012-12-31
WO2011130834A1 (en) 2011-10-27
WO2011130834A8 (en) 2013-01-10
IL222568A (en) 2017-05-29
EP2563349A4 (en) 2014-03-19
CA2797098C (en) 2019-03-26
EP2563349A1 (en) 2013-03-06
CA2797098A1 (en) 2011-10-27
JP2017186346A (ja) 2017-10-12
JP6572256B2 (ja) 2019-09-04

Similar Documents

Publication Publication Date Title
JP6572256B2 (ja) 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用
CN102215874B (zh) 活性剂的聚合物递送系统
JP5981514B2 (ja) タキサン含有両親媒性ブロック共重合体ミセル組成物及びその製造方法
Xiong et al. Vesicles from Pluronic/poly (lactic acid) block copolymers as new carriers for oral insulin delivery
US20180325861A1 (en) Novel cannabinoid formulations
TW200820991A (en) Nanoparticulate sorafenib formulations
WO2011088688A1 (zh) 以氨基酸为稳定剂的聚合物胶束载药系统
JP6605047B2 (ja) 疼痛治療のためのセレコキシブの経口用組成物
JP2020524712A (ja) 二重コア−シェル構造を有する乱溶性カンプトテシン化合物を含む粒子、薬剤学的組成物及びその製造方法
JP5850518B2 (ja) 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤
Zhao Self-nanoemulsifying drug delivery systems (SNEDDS) for the oral delivery of lipophilic drugs
Muruganantham et al. Potentiating the solubility of BCS class II drug zaltoprofen using nanodispersion technology
Elsebay et al. Nanosuspension: a formulation technology for tackling the poor aqueous solubility and bioavailability of poorly soluble drugs
Nagar et al. Synthesis, characterization and evaluation of retinoic acid-polyethylene glycol nanoassembly as efficient drug delivery system
Patel et al. Bedaquiline loaded Soluplus® micelles for improving solubility and intestinal permeability: formulation, optimization, and ex vivo evaluation
CN105012234B (zh) 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途
CN105395481A (zh) 一种含有姜黄素的聚合物胶束载药系统及其制备方法和应用
CA3067723A1 (en) New oral formulations of belinostat
CN115120611A (zh) 一种no供体型胶束组合物及其制备方法与应用
Yusuf et al. Cellulose‐and Saccharide‐Based Orally Dispersible Thin Films Transform the Solid States and Dissolution Characteristics of Poorly Soluble Curcumin
EP3370701A1 (en) A composition for use in a method for prevention or treatment of human immunodeficiency virus infections
US20180064821A1 (en) Site specific curcumin-polymer molecular complexes and methods of treating colon diseases and inflammation
Mandal et al. Polymersomes in colon targeting
Godfroy Polymeric micelles–the future of oral drug delivery
Alwiswasi et al. Ophthalmic Single and Mixed Polymeric Nanomicelles using Brimonidine as a model drug: Preparation, Characterization, and Physical Properties Evaluation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140409

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140826

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20140826

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20141211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170117